Inhibitors of RAD52 recombination protein and methods using same

1. A method of treating a cancer in a subject in need thereof, wherein the cancer has at least one BRCA1 or BRCA2 mutation, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I):

wherein

R 1 is selected from the group consisting of:

wherein, in R 1 : R 4 is selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, and —(C 1 -C 6 )heteroalkyl, and R 5 is selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, and —(C 1 -C 6 )heteroalkyl;

R 2 is —NR 4 R 5 , wherein in R 2 each occurrence of R 4 and R 5 is independently selected from the group consisting of hydrogen, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )heteroalkyl, aryl, and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted, or R 4 and R 5 , together with the nitrogen to which R 4 and R 5 are connected, form —(C 3 -C 10 )heterocyclyl;

R 3 is selected from the group consisting of hydrogen, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 4 -C 6 )heteroalkyl, —F, —Cl, —Br, —CN, —NO 2 , —OR 7 , —SR 7 , —S(═O)R 7 , —S(═O) 2 R 7 , —C(═O)R 7 , —OC(═O)R 7 , and —CO 2 R 7 ;

each occurrence of R 6 is independently selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )heteroalkyl, —(C 2 -C 10 )heterocyclyl, aryl, and heteroaryl, wherein the —(C 3 -C 10 )heterocyclyl, aryl or heteroaryl group is optionally substituted;

each occurrence of R 7 is independently selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )heteroalkyl, —(C 3 -C 6 )cycloalkyl, —(C 4 -C 10 )heterocyclyl, aryl, and —(C 5 -C 10 )heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl group is optionally substituted;

X at 1-position is N and X at 3-position is CH;

Y is O or S;

n is 0 and R 1 is connected to the aryl ring at the 6, 7, or 8 position;

a salt, solvate, tautomer, enantiomer, diastereoisomer, or N-oxide thereof; and any combinations thereof.

2. The method of claim 1 , wherein the method further comprises administering to the subject at least one additional therapeutic agent that treats cancer.

3. A method of treating a cancer in a subject in need thereof, wherein the cancer has at least one BRCA1 or BRCA2 mutation, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

1-(3-(diethylamino)propyl)-3-(3-(dimethylamino)propyl)-1-((6-oxo-5,6-dihydro-[1,3]dioxolo[4,5-g]quinolin-7-yl)methyl)thiourea;

1-(2-((2-aminoethyl)(methyl)amino)-4-methylquinolin-6-yl)-3-(3-(4-ethylpiperazin-1-yl)propyl)thiourea;

1-(3-(butyl(ethyl)amino)propyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(3-(dipropylamino)propyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)-3-(3-(4-methylpiperazin-1-yl)propyl)thiourea;

1-(2-(diethylamino)ethyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(2-(diethylamino)ethyl)-3-(4-methyl-2-(4-ethylpiperazin-1-yl)quinolin-6-yl)thiourea;

a salt, solvate, tautomer, enantiomer, diastereoisomer, or N-oxide thereof, and any combinations thereof.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of squamous cell cancer, lung cancer, vulval cancer, thyroid cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and neck cancer.

5. The method of claim 1 , wherein the cancer is ovarian cancer or breast cancer.

6. A method of treating ovarian or breast cancer in a subject in need thereof, wherein the cancer has at least one BRCA1 or BRCA2 mutation, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I):

wherein in (I):

R 1 is selected from the group consisting of:

wherein, in R 1 : R 4 is selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, and —(C 1 -C 6 )heteroalkyl, and R 5 is selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl; and —(C 1 -C 6 )heteroalkyl;

R 2 is —NR 4 R 5 , wherein in R 2 each occurrence of R 4 and R 5 is independently selected from the group consisting of hydrogen, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )heteroalkyl, aryl; and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted, or R 4 and R 5 , together with the nitrogen to which R 4 and R 5 are connected, form —(C 3 -C 10 )heterocyclyl;

R 3 is selected from the group consisting of hydrogen, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )heteroalkyl, —F, —Cl, —Br, —CN, —NO 2 , —OR 7 , —SR 7 , —S(═O)R 7 , —S(═O) 2 R 7 , —C(═O)R 7 , —OC(═O)R 7 , and —CO 2 R 7 ;

each occurrence of R 6 is independently selected from the group consisting of —(C 1 -C 6 )alkyl, —(C 1 -C 6 )heteroalkyl, —OR 7 , —(C 3 -C 10 )heterocyclyl, aryl, and heteroaryl, wherein the —(C 3 -C 10 )heterocyclyl, aryl or heteroaryl group is optionally substituted;

each occurrence of R 7 is independently selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )heteroalkyl, —(C 3 -C 6 )cycloalkyl, —(C 4 -C 10 )heterocyclyl, aryl, and —(C 5 -C 10 )heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl group is optionally substituted;

X at 1-position is N and X at 3-position is CH;

Y is O or S;

n is 0 and R 1 is connected to the aryl ring at the 6, 7, or 8 position;

or a salt; solvate, tautomer, enantiomer, diastereoisomer, or N-oxide thereof, and any combinations thereof.

7. The method of claim 6 , the method further comprising administering to the subject at least one additional therapeutic agent that treats cancer.

8. A method of treating ovarian or breast cancer—in a subject in need thereof, wherein the cancer has at least one BRCA1 or BRCA2 mutation, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

1-(3-(diethylamino)propyl)-3-(3-(dimethylamino)propyl)-1-((6-oxo-5,6-dihydro-[1,3]dioxolo[4,5-g]quinolin-7-yl)methyl)thiourea;

1-(2-((2-aminoethyl)(methyl)amino)-4-methylquinolin-6-yl)-3-(3-(4-ethylpiperazin-1-yl)propyl)thiourea;

1-(3-(butyl(ethyl)amino)propyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(3-(dipropylamino)propyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(4-methyl-2-(4-methyl piperazin-1-yl)quinolin-6-yl)-3-(3-(4-methylpiperazin-1-yl)propyl)thiourea;

1-(2-(diethylamino)ethyl)-3-(4-methyl-2-(4-methylpiperazin-1-yl)quinolin-6-yl)thiourea;

1-(2-(diethylamino)ethyl)-3-(4-methyl-2-(4-ethylpiperazin-1-yl)quinolin-6-yl)thiourea;

a salt, solvate, tautomer, enantiomer, diastereoisomer, or N-oxide thereof, and any combinations thereof.

9. The method of claim 3 , wherein the cancer is selected from the group consisting of squamous cell cancer, lung cancer, vulval cancer, thyroid cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and neck cancer.

10. The method of claim 3 , wherein the cancer is ovarian cancer or breast cancer.